GLP-1 injections are a powerful tool in medical weight loss, helping individuals achieve their weight loss goals by reducing appetite and improving insulin sensitivity
A recent randomized study comparing structured lifestyle modification (a cornerstone in the currently recommended treatment of NASH) to liraglutide 3 mg/day without lifestyle modifications showed similar reductions in ALT and liver stiffness with no difference in bodyweight variations
Referral to certified lymphedema therapists (CLT-LANA) and specialized lymphedema clinics is appropriate for complex cases, inadequate response to initial therapy, or when surgical evaluation is warranted
Using GLP-1 receptor agonists like semaglutide may increase your risk of acute pancreatitis
In the SURMOUNT-1 trial , participants receiving the highest dose of Tirzepatide lost an average of 20.9% of their body weight over 72 weeks , a result significantly greater than typical outcomes with Semaglutide
Of course, its not a magic bullet